Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202772 · ClinicalTrials.gov registry record · Phase 1
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
A Phase 1 study of Urothelial Carcinoma of the Urinary Bladder, sponsored by Guarionex J. Decastro.
- Active
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02202772 is a Phase 1 study of Urothelial Carcinoma of the Urinary Bladder that is active but no longer recruiting, run by Guarionex J. Decastro. The registered enrollment target is 51 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02202772, a Phase 1 study of Urothelial Carcinoma of the Urinary Bladder, is active but no longer recruiting, sponsored by Guarionex J. Decastro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Cabazitaxel
Study Locations (1)
New York
- Columbia University Irving Medical Center - HIP - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-12-01 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02202772
The ClinicalTrials.gov registry entry for NCT02202772 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Guarionex J. Decastro, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urothelial Carcinoma of the Urinary Bladder appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02202772 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02202772 about?
NCT02202772 is a clinical study titled "Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder". The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxic...
What is the current status of trial NCT02202772?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2014-12-01. Estimated completion is 2028-04.
What conditions does trial NCT02202772 study?
This clinical trial studies the following conditions: Urothelial Carcinoma of the Urinary Bladder.
What interventions are being tested in trial NCT02202772?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT02202772?
This trial is sponsored by Guarionex J. Decastro, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02202772 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.